No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
LigaChem Biosciences, Inc. specializes in the development and manufacturing of a broad spectrum of medical solutions, encompassing pharmaceuticals, medical devices, and essential healthcare supplies. Their extensive product offerings include various therapeutic agents such as antibiotics, anti-coagulants, and oncology treatments, alongside cutting-edge antibody-drug conjugates and protein-drug conjugates. Established on May 2, 2006, the company's headquarters are situated in Daejeon, South Korea.
ligachembio.comNo one on the platform currently holds 141080.KQ.
No tracked institution reports a position in 141080.KQ as of their last filing.
No one on the platform has traded 141080.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 12.4% | 23.4% | ||||
| Profit Margin % | -52.5% | -94.0% | -70.9% | |||
| Free Cash Flow Margin % | -90.1% | -89.3% | -67.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $157.7B | -5.3% | $-3154.62 | $-3839.44–$-3129.10 | — | 1 |
| 2027 | $303.0B | +92.2% | $-1931.85 | $-33004.85–$-1916.22 | — | 5 |
| 2028 | $307.3B | +1.4% | $82.55 | $81.89–$100.47 | — | 2 |
| 2029 | $280.0B | -8.9% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-1943.02 | $-1769.21 | +8.9% |
| 2026-05-15 | $-365.26 | $-1024.48 | -180.5% |
| 2026-02-13 | $-1781.15 | $-1498.21 | +15.9% |
| 2025-11-14 | $363.09 | $-429.30 | -218.2% |
| 2025-08-14 | $326.31 | $-842.77 | -358.3% |
| 2025-05-15 | $688.34 | $729.64 | +6.0% |
| 2025-02-14 | $729.64 | $-149.06 | -120.4% |
| 2024-11-14 |
| $106.59 |
| $330.00 |
| +209.6% |
| -2.46% |
| $3.50T |
| — |
| 302440.KSSK bioscience Co.,Ltd. | $36750.00 | -2.78% | $2.88T | — |
| 310210.KQVoronoi, Inc. | $141500.00 | -2.68% | $2.59T | — |
Source: Financial Modeling Prep · peers by sector/industry